Friday, 21 Sep 2018

You are here

Time to Rethink Gout as a Chronic Disease

The current issue of JAMA has a perspective article on Gout’s bad rap as dietary disease rather than the complex, chronic inflammatory disorder that is ineffectively treated in many. 

The author and experts interviewed believe that the pipeline of new drugs for gout will fuel the future of evidence-based care and more informed lifestyle instruction.

Gout affects about 4% of adults in the United States. The growing number of older adults, who are more likely to have gout, is expected to increase the need for gout care.

"The disease of kings" is clearly a misnomer as gluttony and excess seldom stand in the way of better care.  Sadly, many with gout fail to recognize it as a form of arthritis,  A 2016 online survey showed that 71% didn’t know gout and that half with gout were embarrassed by their condition. 

Although diet is often implicated, evidence proving the benefits of strict avoidance are limited.  While red meat, alcohol, sugar-sweetened soft drinks, and seafood have been implicated, the ACR guideline suggests that avoidance of purine-rich organ meats (liver), shellfish and sardines may only improve serum uric acid levels by10% to 18%.

Many experts have noted the limitations and pitfalls with found with a dietary approach to gout. 

A real problem are the differing treatment approaches and understanding of gout by primary care physicians (PCPs) and rheumatologist, exemplified by their contrasting guidelines. The 2012 ACR focuses on a a treat-to-target approach with the goal of a uric acid levels below 6 mg/dL and the use of urate-lowering medications long-term with frequent monitoring.  Yet the 2016 American College of Physicians guideline only has a treat-to-symptoms approach emphasizing the use of anti-inflammatory medications to control flares and reserving uric acid-lowering therapy for patients with frequent flares, 

Discrepancies between the guidelines may be hampering patient care, and hopefully upcoming meetngs between the ACR and ACP may resolve these differences. The ACR’s gout guideline is scheduled for release in 2020.

Emerging evidence suggests that a chronic disease care model for gout, which simultaneously addresses uric acid levels, lifestyle, and dietary factors, may improve management and outcomes for patients with gout.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Quarterly Canakinumab Reduces Gout Risk Without Affecting Uric Acid

The Annals of Internal Medicine reports that interleukin-1 (IL-1) inhibitor treatment is associated with a reduced risk of gout attacks - such are the findings of an anlysis of the CANTOS study previously reported at the Annual ACR 2017 meeting in Washington, DC. 

Usual Allopurinol Doses Insufficient in CKD Patients

Uric acid (sUA) control may be a challenge in patients with chronic kidney disease (CKD). A cohort study shows that conventional dosing recommendations for allopurinol are unlikely to reach target serum sUA goals.

Sleep Apnea Raises Gout Risk

Patients with obstructive sleep apnea were at increased risk for incident gout, particularly in the first years after the sleep apnea diagnosis, U.K. researchers reported.

In a large retrospective cohort study, the adjusted hazard ratio for a new gout diagnosis among individuals with sleep apnea was 1.42 (95% CI 1.29-1.56), according to Milica Blagojevic-Bucknall, PhD, of Keele University in Keele, England, and colleagues.

Adherence to Gout Therapies Painfully Low

A retrospective study of the large UK Clinical Practice Research Datalink assessed patient compliance in gout and found that adherence to allopurinol is poor, especially among females and younger patients and those with fewer comorbidities.

Not All Hyperuricemia Leads to Gout

Dalbeth and colleagues studied 4 large prospective cohorts and found that rising levels of serum uric acid (SUA) leads to a non-linear increased risk of incident gout, but only half of those with SUA ≥10mg/dL developed clinically evident gout.